HAYWARD, Calif., Oct. 19 /PRNewswire/ -- Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today the President and Chief Executive Officer Harold Van Wart, Ph.D. will be featured on a panel at the annual BIO InvestorForum meeting in San Francisco today.
The session, “The Impact of Research on the Growing Diabetes Epidemic,” will be held at 3:30 p.m. in the Telegraph room of the Palace Hotel.
About Metabolex
Metabolex is a privately held biotechnology company dedicated to the discovery and development of novel therapeutics to transform the treatment of diabetes and related metabolic disorders. Metabolex has drawn on its deep understanding of diabetes to create the largest database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company’s clinical program is focused on developing next- generation insulin sensitizers that lower blood glucose without the serious safety and tolerability issues associated with currently marketed products. Metabolex is partnering with Ortho-McNeil, a Johnson & Johnson company, to develop and commercialize products for diabetes and metabolic disease, including Metabolex’s lead drug candidate, metaglidasen, a second-generation insulin sensitizer now in a Phase 2/3 clinical trial. For additional information about Metabolex and its development pipeline, visit www.metabolex.com.
Metabolex, Inc.
CONTACT: Mark Bagnall of Metabolex, +1-510-293-8800 ormbagnall@metabolex.com; or Brian Reid of WeissComm Partners,+1-703-402-3626 or breid@weisscommpartners.com, for Metabolex
Web site: http://www.metabolex.com/
